Strategic

战略性的

investment

投资

in

在

Germany-based

总部位于德国

PAD

垫

Aviation,

航空

a

一个

premier

总理

European

欧洲的

private

私有

aviation

航空

operator,

操作员，

lays

放置

the

这

foundation

基础

for TransMedics to establish a dedicated organ transplantation air logistics network across

以便TransMedics建立覆盖全国的专用器官移植航空物流网络

Europe

欧洲

ANDOVER, Mass.

马萨诸州安多弗

,

，

July 6, 2026

2026年7月6日

/PRNewswire/ -- TransMedics Group, Inc. ('TransMedics') (Nasdaq:

/美通社/ -- TransMedics Group, Inc.（“TransMedics”）（纳斯达克：

TMDX

TMDX

), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart, and liver failure, today announced the closing of its strategic investment in PAD Aviation, a premier Germany-based private aviation operator.

），一家正在为终末期肺、心和肝衰竭患者变革器官移植疗法的医疗技术公司，今日宣布完成对PAD Aviation的战略投资。PAD Aviation是一家总部位于德国的顶级私人航空运营商。

The investment in PAD Aviation is a critical step forward for TransMedics' ongoing efforts to replicate the OCS NOP model in Europe to expand the adoption of the OCS perfusion technology and establish a dedicated pan-European organ transplant air and ground logistics network to support transplant activities across the European Union.

对PAD Aviation的投资是TransMedics在欧洲复制OCS NOP模式、扩大OCS灌注技术的采用，并建立专用的泛欧洲器官移植空中和地面物流网络以支持整个欧盟的移植活动这一持续努力中的关键一步。

'We are thrilled to partner with the PAD Aviation team and to welcome them to our TransMedics family. Together, we can create a significant opportunity to increase the utilization of precious donor organs to save more European transplant patients,' said Waleed Hassanein, M.D., President and Chief Executive Officer of TransMedics..

TransMedics 总裁兼首席执行官 Waleed Hassanein 博士表示：“我们非常高兴能与 PAD Aviation 团队建立合作伙伴关系，并欢迎他们加入 TransMedics 大家庭。携手合作，我们将创造重大机遇，提高珍贵捐赠器官的利用率，从而挽救更多欧洲移植患者。”

About PAD Aviation service GmbH

关于 PAD Aviation 服务有限责任公司

Founded in 2006, PAD Aviation is a leading European business aviation operator, independent of commercial airlines. The company operates from its 24/7 hub in Paderborn, Germany, offering maximum flexibility—particularly for time-critical missions such as organ transport. From its centrally located base, PAD Aviation's aircraft can rapidly reach destinations across Europe.

PAD Aviation 成立于2006年，是欧洲领先的公务航空运营商，独立于商业航空公司。该公司以其位于德国帕德博恩的全天候枢纽为基地，提供最大的灵活性——尤其适用于器官运输等时间紧迫的任务。凭借其中心位置的基地，PAD Aviation 的飞机能够迅速抵达欧洲各地的目的地。

The company operates a modern fleet, including nine Embraer Phenom 300 aircraft, and employs more than 40 highly trained and type-rated pilots. PAD Aviation holds a valid EASA Air Operator Certificate (AOC)..

该公司运营着一支现代化机队，包括九架巴航工业飞鸿300（Embraer Phenom 300）飞机，并雇佣了40多名经过严格训练、具备相应机型资质的飞行员。PAD Aviation持有有效的欧洲航空安全局（EASA）航空运营商证书（AOC）。

About TransMedics Group, Inc.

关于 TransMedics 集团公司

TransMedics is the world's leader in portable extracorporeal warm perfusion and assessment of donor organs for transplantation. Headquartered in Andover, Massachusetts, the company was founded to address the unmet need for more and better organs for transplantation and has developed technologies to preserve organ quality, assess organ viability prior to transplant, and potentially increase the utilization of donor organs for the treatment of end-stage heart, lung, and liver failure..

TransMedics 是全球便携式体外常温灌注及移植供体器官评估领域的领导者。公司总部位于马萨诸塞州安多弗，成立的初衷是为了解决移植领域对更多、更优质器官的未满足需求，并开发了相关技术，用于保持器官质量、在移植前评估器官活力，以及潜在提高供体器官在治疗终末期心、肺和肝衰竭中的利用率。

Forward-Looking Statements

前瞻性陈述

This press release contains forward-looking statements. These forward-looking statements address various matters, including, among other things, the anticipated benefits of the strategic investment, including the establishment of a dedicated pan-European air and ground logistics network to support transplant activities across the European Union; our strategy of replicating our U.S.

本新闻稿包含前瞻性陈述。这些前瞻性陈述涉及诸多事项，其中包括战略投资的预期收益，包括建立专用的泛欧空运和陆运物流网络，以支持整个欧盟的移植活动；以及我们复制美国业务的战略。

NOP model in Europe; and our efforts to expand the adoption of the OCS technology and increase utilization of donor organs in Europe; .

欧洲的NOP模型；以及我们为推动欧洲地区OCS技术的普及和提高捐献器官利用率所做的努力；。

[1]

[1]

. For this purpose, all statements other than statements of historical facts are forward-looking statements. The words 'believe,' 'may,' 'will,' 'estimate,' 'continue,' 'anticipate,' 'intend,' 'expect,' 'should,' 'could,' 'target,' 'predict,' 'seek' and similar expressions are intended to identify forward-looking statements.

为此，除历史事实陈述外的所有陈述均为前瞻性陈述。“相信”、“可能”、“将会”、“估计”、“继续”、“预期”、“打算”、“期望”、“应当”、“可以”、“目标”、“预测”、“寻求”等词语及类似表述旨在识别前瞻性陈述。

These forward-looking statements are subject to a number of risks and uncertainties. Management cannot predict all risks, nor can we assess the impact of all factors or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in or implied by any forward-looking statements we may make.

这些前瞻性陈述受多种风险和不确定性的影响。管理层无法预测所有风险，也无法评估所有因素的影响，或任何单一因素或因素组合在多大程度上可能导致实际结果与我们可能作出的任何前瞻性陈述中包含或暗示的结果存在重大差异。

In light of these risks and uncertainties, the forward-looking events and circumstances discussed in this press release may not occur and actual results could differ materially and adversely from those anticipated in or implied by the forward-looking statements. Some of the key factors that could cause actual results to differ include: risks and uncertainties related to the strategic investment in PAD Aviation; the effects of the transaction (or the announcement thereof) on relationships with associates, customers, manufacturers, suppliers, employees, other business partners or governmental entities; transaction costs; the risk that the transaction will divert management's attention from our ongoing business operations or otherwise disrupts our ongoing business operations; risks related to the ability to integrate PAD Aviation with TransMedics, including retaining key employees; risks related to operating an aviation business; risks related to the ability to further grow and enhance the National OCS Program; and other factors described in our filings with the Securities and Exchange Commission (the '.

鉴于这些风险和不确定性，本新闻稿中讨论的前瞻性事件和情况可能不会发生，实际结果可能与前瞻性陈述中预期或暗示的结果存在重大且不利的差异。可能导致实际结果出现差异的一些关键因素包括：与对PAD Aviation进行战略投资相关的风险和不确定性；交易（或其公告）对与关联方、客户、制造商、供应商、员工、其他业务合作伙伴或政府实体关系的影响；交易成本；交易可能分散管理层对我们持续业务运营的注意力或以其他方式扰乱我们持续业务运营的风险；与将PAD Aviation整合到TransMedics相关的能力风险，包括留住关键员工；与运营航空业务相关的风险；与进一步发展和增强国家OCS项目能力相关的风险；以及我们在向美国证券交易委员会提交的文件中描述的其他因素（“

Investor Contact:

投资者联系：

Brian Johnston

布莱恩·约翰斯顿

Gilmartin Group

吉尔马丁集团

[email protected]

[email protected]

SOURCE TransMedics Group, Inc.

来源：TransMedics Group, Inc.

21

二十一

%

%

more press release views with

更多新闻稿浏览量

Request a Demo

申请演示